217.5401 Definitions for KRS 217.5401 to 217.5408. As used in KRS 217.5401 to 217.5408: (1) (2) (3) (4) (5) (6) (7) "Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, protein other than a chemically synthesized polypeptide, allergenic product or analogous product, or arsphenamine or derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings; "Device" has the same meaning as in KRS 217.015; "Drug" has the same meaning as in KRS 217.015; "Eligible patient" means an individual who meets the requirements of KRS 217.5403; "Health care provider" means a licensed physician, a licensed advanced practice registered nurse, or a licensed physician assistant; "Health facility" has the same meaning as in KRS 216B.015; "Investigational drug, biological product, or device" means a drug, biological product, or device that: (a) Has successfully completed Phase I of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration; and (b) Remains under investigation in a United States Food and Drug Administration-approved clinical trial; (8) "Terminal illness" means a progressive disease or a medical or surgical condition that: (a) Entails significant functional impairment; (b) Is not considered by a treating health care provider to be reversible even with administration of a treatment currently approved by the United States Food and Drug Administration; and (c) Without life-sustaining procedures, will result in death; and (9) "Written informed consent" means a written document that meets the requirements of KRS 217.5404. Effective: June 29, 2017 History: Created 2017 Ky. Acts ch. 65, sec. 1, effective June 29, 2017.